Imperagen, a Manchester-based BioTech spin-out from the University of Manchester, has closed €5.8 mi...
The AMW Read
Incremental seed-stage addition to the AI biotech player map; platform approach is novel but not yet validated at scale.
Imperagen, a Manchester-based BioTech spin-out from the University of Manchester, has closed €5.8 million (£5 million) in Seed funding to accelerate R&D, expand wet lab capacity, and build go-to-market functions. The round was led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone, bringing total funding to €9.8 million. Guy Levy-Yurista joins as CEO.
The company combines quantum physics simulation, problem-specific AI model training, and automated robotics into a closed-loop system for enzyme engineering. By simulating millions of mutation combinations in silico, training targeted AI models on those outputs, and validating predictions via wet lab robotics, the platform iteratively improves enzyme performance. Imperagen reports improving productivity of two enzymes by 677x and 572x in just five rounds, and already works with a Fortune 500 personal care company.
Why it matters: Imperagen exemplifies the emerging 'closed-loop biology' pattern — an AI-native approach that merges in silico simulation, active learning, and experimental validation into a self-improving system. This contrasts with traditional manual screening and zero-shot prediction methods that often fail in real-world industrial conditions. The company targets pharmaceutical manufacturing, sustainable chemistry, and industrial biotech — segments where AI-driven enzyme design can unlock faster, cheaper product development. However, at €5.8M Seed, this is an early-stage bet; the platform must demonstrate scalable commercial traction beyond initial customer wins. #AIbio #enzymeengineering #closedloop #biotechAI #UKdeeptech #industrialbiotech
